Cellectis S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated February 8, 2023, reports on a capital raising event by Cellectis S.A., a foreign private issuer headquartered in Paris, France. The filing details the completion of a public offering of American Depositary Shares (ADSs) and the subsequent exercise of an underwriters' option.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data relates to the equity offering:
- Offering Price: $2.50 per ADS.
- Firm Shares: 8,800,000 ordinary shares (delivered as 8,800,000 ADSs).
- Option Shares Exercised: 1,107,800 ordinary shares (delivered as 1,107,800 ADSs).
- Total Shares Issued in Offering: 9,907,800 ordinary shares (9,907,800 ADSs).
- Underwriters: Jefferies LLC and Barclays Capital Inc.
Material Changes
The material change reported is the increase in the Company's share capital following the full exercise of the underwriters' option to purchase additional shares on February 7, 2023. The option was originally for up to 1,320,000 shares, of which 1,107,800 were purchased.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the standard legal disclaimer that the report does not constitute an offer to sell securities. The document primarily serves to incorporate legal opinions regarding the validity of the shares issued.
Investor Verification Checklist
- Verify the total gross proceeds from the offering by multiplying the total shares issued (9,907,800) by the offering price ($2.50).
- Confirm the updated total number of outstanding shares and ADSs post-offering in subsequent filings.
- Review the legal opinion filed as Exhibit 5.1 for any conditions attached to the share issuance.
- Check for any use of proceeds disclosures in related press releases or the Form F-3 registration statement.